Send me real-time posts from this site at my email
Motley Fool

Johnson & Johnson Coronavirus Vaccine Wins FDA Authorization

The U.S. now has a third coronavirus vaccine authorized for use. Johnson & Johnson's (NYSE: JNJ) vaccine, developed by its subsidiary Janssen, received Emergency Use Authorization (EUA) from the FDA on Saturday. This followed a unanimous vote by the regulator's vaccines and related biological products advisory committee that it do so.

In contrast to the two shots required for both of the other FDA-authorized coronavirus vaccines -- Moderna's (NASDAQ: MRNA) mRNA-1273 and Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) BNT162b2 -- Johnson & Johnson's is a one-shot inoculation.

Image source: Getty Images.

It also has relatively less burdensome storage requirements, as it can be kept for as long as three months in standard refrigeration temperatures of 36 to 46 degrees Fahrenheit.

The Johnson & Johnson vaccine demonstrated notably lower efficacy (72%) in late-stage testing compared the 95% or so of its two peers. However, 72% is still considered unusually high by vaccine development standards, plus Johnson & Johnson's was shown to be 100% efficacious in preventing hospitalization and death.

The Moderna and Pfizer/BioNTech shots were authorized in December and so far have been administered to nearly 15% of the U.S. population So it's likely that Johnson & Johnson's jab won't lap past them, no matter its advantages. It will, however, help push the inoculation rate up quickly.

Investors should be aware that Johnson & Johnson won't be making money from the vaccine during the pandemic. As it reiterated in the press release trumpeting the EUA, it will provide the jab "on a not-for-profit basis for emergency pandemic use."

The company added that it has already started to ship the vaccine, with the goal of delivering enough to inoculate over 20 million people in this country by the end of March. 100 million doses should by shipped by the end of June.

10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of February 24, 2021

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.


Source

Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue